Research Paper Volume 14, Issue 13 pp 5427—5448

Development of a prognostic signature based on immune-related genes and the correlation with immune microenvironment in breast cancer

Menglu Dong1, , Xiaoqing Cui1, , Ge Wang1, , Qi Zhang2, , Xingrui Li1, ,

  • 1 Department of Thyroid and Breast Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
  • 2 Department of Plastic and Cosmetic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

Received: November 16, 2021       Accepted: May 30, 2022       Published: July 5, 2022      

https://doi.org/10.18632/aging.204158
How to Cite

Copyright: © 2022 Dong et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Breast cancer (BC) is an inflammatory tumor caused by a variety of pathological factors, and is still the most common malignant tumor in women. Immune-related genes (IRGs) play a prominent role in the oncogenesis and progression of BC, and are of tumor-specific expression patterns that would benefit the prognosis evaluation. However, there were no systematic studies concerning the possibilities of IRGs in BC prognosis. In this study, the Cancer Genome Atlas (TCGA) database was used to integrate the expression profiles of IRG with the overall survival (OS) rate of 1039 breast cancer patients. The Cox regression analysis was used to predict the survival-related IRGs in BC. Then, we successfully screened a total of 6 IRGs, including PSME2, ULBP2, IGHE, SCG2, SDC1, and SSTR1, and accordingly constructed a prognosis prediction model of BC. Based on the IRG-related model, the BC patients were divided into high- and low-risk groups, and the association between the prognostic model and tumor immune microenvironment (TME) was further explored. The prognostic model reflected the infiltration of various immune cells. Moreover, the low-risk group was found to be with higher immunophenoscore and distinct mutation signatures compared with the high-risk group. The histological validation showed that SDC1, as well as M2 macrophage biomarker CD206, were both of higher abundance in BC samples of high-risk patients, compared with those of low-risk patients. Our results identify the clinically significant IRGs and demonstrate the importance of the IRG-based immune prognostic model in BC monitoring, prognosis prediction, and therapy.

Abbreviations

AUC: area under the curve; BC: breast cancer; CRC: colorectal cancer; DEGs: differentially expressed genes; FDR: false discovery rate; GO: Gene Ontology; GSEA: Gene Set Enrichment Analysis; GGI: Genomic Grade Index; IRGs: immune-related genes; ImmPort: Immunology Database and the Analysis Portal; KEGG: Kyoto Encyclopedia of Genes and Genomes; LASSO: least absolute shrinkage selection operator; ICIs: immune checkpoints-inhibitors; NKG2D: natural killer group 2 member D; NK: Natural killer; OS: overall survival; PCA: principal components analysis; PD-L1: programmed cell death-ligand 1; PD1: programmed death 1; ssGSEA: single-sample gene-set enrichment analysis; TCGA: The Cancer Genome Atlas; TFs: transcription factors; TME: tumor microenvironment; TMB: tumor mutation burden.